Middle East and Africa Custom Antibody Market Outlook and Strategic Insights by 2028

The custom antibody market in Middle East and Africa is expected to grow from US$ 14.0 million in 2021 to US$ 25.0 million by 2028; it is estimated to grow at a CAGR of 8.6% from 2021 to 2028.

Antibodies, including monoclonal and polyclonal, find applications in academic, research, and pharmaceutical institutes and organizations. Using these antibodies, institutes and organizations conduct several research and development activities for drug and biomarker developments, and other therapeutic and clinical diagnostics product developments.  Custom antibodies are widely preferred in research to differentiate the antibody products. These antibodies are continuously evaluated to provide safe, accurate, and efficient products with improved quality. Small and medium-sized companies have increased their research and development investments and activities exponentially. Such investments have escalated the demand for custom antibodies.

The pandemic has affected the research and development activities in these countries. Apart from this, a considerable population already faces a growing burden of non-communicable diseases, making them more vulnerable to the virus. Moreover, economic uncertainties and ongoing conflicts are worsening the condition in the region. For instance, countries such as Syria, Libya, and Yemen are suffering violent conflict and have been unable to implement any public health measures. In addition, Iran was in a deep economic recession due to the US sanctions. These factors are expected to impact the growth of the market in the region negatively. In addition, the primary source of economic stabilization in Middle East countries is oil production and export. However, the current pandemic is creating turbulence in the economics of the Middle East region. An immediate drop in domestic and external demand for goods and products, primarily crude oil, and halted production due to labor deficiency are significant impacts observed in the region. Additionally, tightened financial condition is also decreasing the overall economic activities in the area. This uncertainty with average delays often associated with regulatory approvals in low- and middle-income countries is hindering the market's growth.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the custom antibody market. The Middle East and Africa Custom antibody market is expected to grow at a good CAGR during the forecast period.

Middle East and Africa Custom Antibody Market Segmentation

By Service

• Antibody Development
• Antibody Production and Purification
• Antibody Fragmentation and Labelling

By Type

• Monoclonal Antibodies
• Polyclonal Antibodies
• Other Custom Antibodies

By Source

• Mice
• Rabbits
• Others

By Research Area

• Oncology
• Immunology
• Stem Cells
• Infectious Diseases
• Neurobiology
• Cardiovascular Diseases
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations

By Country

• Middle East and Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East and Africa

Companies Mentioned

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Merck KGAA
• Abcam
• Genscript
• Agilent Technologies, Inc.

Middle East and Africa Custom Antibody Report Scope